YU13902A - Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives - Google Patents

Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Info

Publication number
YU13902A
YU13902A YU13902A YUP13902A YU13902A YU 13902 A YU13902 A YU 13902A YU 13902 A YU13902 A YU 13902A YU P13902 A YUP13902 A YU P13902A YU 13902 A YU13902 A YU 13902A
Authority
YU
Yugoslavia
Prior art keywords
mesoprogestins
female
progesterone receptor
component
contraception
Prior art date
Application number
YU13902A
Other languages
Serbo-Croatian (sh)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of YU13902A publication Critical patent/YU13902A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of mesoprogestins for the production of a pharmaceutical for female contraception, to a pharmaceutical preparation for female contraception and to a method of female contraception administering effective amounts of a mesoprogestin in a female desiring contraception. Optionally the mesoprogestin can be used in combination with an estrogen. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.
YU13902A 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives YU13902A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
YU13902A true YU13902A (en) 2006-01-16

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
YU13902A YU13902A (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Country Status (28)

Country Link
EP (1) EP1605949A2 (en)
JP (1) JP2003511399A (en)
KR (1) KR20020038745A (en)
CN (1) CN1384748A (en)
AR (1) AR025455A1 (en)
AU (1) AU781835B2 (en)
BG (1) BG106441A (en)
BR (1) BR0013711A (en)
CA (1) CA2383650A1 (en)
CO (1) CO5190694A1 (en)
CZ (1) CZ2002707A3 (en)
EA (1) EA006805B1 (en)
EE (1) EE200200103A (en)
HR (1) HRP20020265A2 (en)
HU (1) HUP0202515A3 (en)
IL (1) IL148415A0 (en)
LT (1) LT5001B (en)
LV (1) LV12940B (en)
MX (1) MXPA02002186A (en)
NO (1) NO20020998L (en)
NZ (1) NZ517470A (en)
PE (1) PE20010579A1 (en)
PL (1) PL353994A1 (en)
SI (1) SI20853A (en)
SK (1) SK2982002A3 (en)
UA (1) UA77150C2 (en)
WO (1) WO2001026603A2 (en)
YU (1) YU13902A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE338763T1 (en) * 2002-08-02 2006-09-15 Schering Ag PROGESTERONE RECEPTOR MODULATORS WITH INCREASED ANTIGONADOTROTIC ACTIVITY FOR FEMALE FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY
DE10236405A1 (en) 2002-08-02 2004-02-19 Schering Ag New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
AR049707A1 (en) * 2004-07-07 2006-08-30 Wyeth Corp CYCLE PROGESTINE REGIMES AND KITS
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
WO2010119029A1 (en) 2009-04-14 2010-10-21 Laboratoire Hra-Pharma Method for on-demand contraception
CN110548034A (en) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 Pregnancy-blocking medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (en) 1936-11-20 1940-11-27 Chemische Ind Ges Process for the preparation of compounds of the estradiol type which are esterified in the 3-position
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (en) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT
FI101601B (en) * 1987-09-24 1998-07-31 Jencap Res Ltd Contraceptive Preparation and Use of Estrogen and Progestin in a Procedure for Preparing a Contraceptive Preparation
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (en) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds
DE4332283A1 (en) * 1993-09-20 1995-04-13 Jenapharm Gmbh Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds
DE4429397C2 (en) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
DE4429398C2 (en) 1994-08-09 1997-09-11 Jenapharm Gmbh Use of Estra-1,3,5 (10) -triene derivatives for hormonal contraception
NZ295365A (en) * 1994-10-24 1999-07-29 Schering Ag Competitive progesterone antagonists for regulating female fertility as required
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
ATE213947T1 (en) * 1996-06-25 2002-03-15 Akzo Nobel Nv PROGESTOGEN-ANTI-PROGESTOGEN THERAPIES
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (en) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
AU4501800A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
CA2383650A1 (en) 2001-04-19
HUP0202515A2 (en) 2002-12-28
BR0013711A (en) 2002-05-07
LT5001B (en) 2003-03-25
EA006805B1 (en) 2006-04-28
WO2001026603A3 (en) 2002-01-17
BG106441A (en) 2002-09-30
LV12940B (en) 2003-06-20
UA77150C2 (en) 2006-11-15
AU3215001A (en) 2001-04-23
JP2003511399A (en) 2003-03-25
AU781835B2 (en) 2005-06-16
MXPA02002186A (en) 2002-09-02
LT2002035A (en) 2002-10-25
PE20010579A1 (en) 2001-06-04
CZ2002707A3 (en) 2002-11-13
PL353994A1 (en) 2003-12-15
NO20020998L (en) 2002-03-14
CN1384748A (en) 2002-12-11
KR20020038745A (en) 2002-05-23
CO5190694A1 (en) 2002-08-29
EE200200103A (en) 2003-04-15
IL148415A0 (en) 2002-09-12
NO20020998D0 (en) 2002-02-28
WO2001026603A2 (en) 2001-04-19
SI20853A (en) 2002-10-31
HRP20020265A2 (en) 2004-02-29
NZ517470A (en) 2004-03-26
EA200200284A1 (en) 2002-10-31
AR025455A1 (en) 2002-11-27
SK2982002A3 (en) 2002-07-02
EP1605949A2 (en) 2005-12-21
HUP0202515A3 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
WO1995011013A3 (en) Combination of progesterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for peri- and post-menopausal women
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2002047693A3 (en) Steroid hormone products comprising a stabilizing agent in non-crystalline form
HUP0103345A3 (en) Use of estrogen receptor modulators in combination with sexual steroid precursors for the preparation of pharmaceutical compositions
WO2004110408A3 (en) Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
CA2222133A1 (en) Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
PL348113A1 (en) Drug delivery device, especially for the delivery of progestins and estrogens
CA2188907A1 (en) Combination compound for contraception based on natural estrogen
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
LT2002035A (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
WO2000074649A3 (en) Ophthalmic histamine compositions and uses thereof
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
WO2001015679A3 (en) Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
JO2606B1 (en) Transdermal Delivery of Hormones without the need of Penetration Enhancers
AU9621598A (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
WO2002056903A3 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
WO2005058287A3 (en) Transdermal delivery system of hormones without penetration enhancers
WO2001034126A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
EP0968713A4 (en) Plasters containing isosorbide nitrate
MXPA01011296A (en) Contraceptive compositions containing indoline derivatives and progestational agents.
WO1996028154A3 (en) Use of anti-oestrogens as male contraceptives
BR0116127A (en) Compound, pharmaceutical composition, use of a compound, and, male contraceptive kit